Product
Help
Pricing
About
Jobs
Log in
Get started
Keyword
Add to collection
SER-109
Description:
An investigational oral microbiome therapy consisting of purified bacterial spores, developed to prevent recurrent Clostridioides difficile infection.
Primary topic:
Clostridium difficile and Clostridium perfringens research (94%)
Related topic:
Clostridium difficile and Clostridium perfringens research (94%)
Wikidata ID:
wiki/Q118113233
OpenAlex ID:
keywords/ser-109
SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection
2022
·
Paul Feuerstadt
, Thomas J. Louie
, et al.
·
New England Journal of Medicine
·
626
PDF
A Novel Microbiome Therapeutic Increases Gut Microbial Diversity and Prevents RecurrentClostridium difficileInfection
2016
·
Sahil Khanna
, Darrell S. Pardi
, et al.
·
The Journal of Infectious Diseases
·
353
Nerve Growth Factor (NGF) Down-regulates the Bcl-2 Homology 3 (BH3) Domain-only Protein Bim and Suppresses Its Proapoptotic Activity by Phosphorylation
2002
·
Subhas C. Biswas
, Lloyd A. Greene
·
Journal of Biological Chemistry
·
196
PDF
Probiotics for prevention of Clostridium difficile infection
2017
·
John P. Mills
, Krishna Rao
, et al.
·
Current Opinion in Gastroenterology
·
193
SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial
2020
·
Barbara H McGovern
, Christopher B Ford
, et al.
·
Clinical Infectious Diseases
·
171
PDF
Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent Clostridioides difficile Infection: A Phase 3, Open-Label, Single-Arm Trial
2023
·
Matthew D. Sims
, Sahil Khanna
, et al.
·
JAMA Network Open
·
97
PDF
Gut microbiota changes associated with Clostridioides difficile infection and its various treatment strategies
2023
·
Anne J. Gonzales-Luna
, Travis J. Carlson
, et al.
·
Gut Microbes
·
71
PDF
SER-109: An Oral Investigational Microbiome Therapeutic for Patients with Recurrent Clostridioides difficile Infection (rCDI)
2022
·
Sahil Khanna
, Matthew Sims
, et al.
·
Antibiotics
·
61
PDF
New and emerging therapies for Clostridium difficile infection
2016
·
Jessica Martin
, Mark Wilcox
·
Current Opinion in Infectious Diseases
·
50
The N-terminal region of ABC50 interacts with eukaryotic initiation factor eIF2 and is a target for regulatory phosphorylation by CK2
2007
·
Sonia Paytubi
, Nicholas A. Morrice
, et al.
·
Biochemical Journal
·
50
Update on microbiota-derived therapies for recurrent Clostridioides difficile infections
2023
·
Nicolas Benech
, Frédéric Barbut
, et al.
·
Clinical Microbiology and Infection
·
36
PDF
Assessment of Quality of Life Among Patients With Recurrent Clostridioides difficile Infection Treated with Investigational Oral Microbiome Therapeutic SER-109: Secondary Analysis of a Randomized Clinical Trial
2023
·
Kevin W. Garey
, Jinhee Jo
, et al.
·
JAMA Network Open
·
34
PDF
Extended Follow-up of Microbiome Therapeutic SER-109 Through 24 Weeks for Recurrent Clostridioides difficile Infection in a Randomized Clinical Trial
2022
·
Stuart H. Cohen
, Thomas J. Louie
, et al.
·
JAMA
·
34
A Comparison of Currently Available and Investigational Fecal Microbiota Transplant Products for Recurrent Clostridioides difficile Infection
2024
·
Yifan Wang
, Aaron Hunt
, et al.
·
Antibiotics
·
32
Microbiota restoration therapies for recurrent Clostridioides difficile infection reach an important new milestone
2024
·
Herbert L. DuPont
, Andrew W. DuPont
, et al.
·
Therapeutic Advances in Gastroenterology
·
31
SER-109 (VOWST™): A Review in the Prevention of Recurrent Clostridioides difficile Infection
2024
·
Hannah A. Blair
·
Drugs
·
30
Prevalence of Comorbid Factors in Patients With Recurrent Clostridioides difficile Infection in ECOSPOR III, a Randomized Trial of an Oral Microbiota–Based Therapeutic
2023
·
Charles S Berenson
, Bret Lashner
, et al.
·
Clinical Infectious Diseases
·
24
PDF
Recurrent Clostridioides difficile Infection: Current Clinical Management and Microbiome-Based Therapies
2023
·
Parul Berry
, Sahil Khanna
·
BioDrugs
·
23
Microbiota restoration for recurrent Clostridioides difficile: Getting one step closer every day!
2021
·
S. Khanna
·
Journal of Internal Medicine
·
23
PDF
Manufacturing Process of SER-109, a Purified Investigational Microbiome Therapeutic, Reduces Risk of Coronavirus Transmission From Donor Stool
2022
·
Christopher McChalicher
, Ahmad Abdulaziz
, et al.
·
Open Forum Infectious Diseases
·
20
PDF
Clostridioides Difficile: A Concise Review of Best Practices and Updates
2024
·
Abdelrahman Yakout
, Yan Bi
, et al.
·
Journal of Primary Care & Community Health
·
18
Impact of a Purified Microbiome Therapeutic on Abundance of Antimicrobial Resistance Genes in Patients With RecurrentClostridioides difficileInfection
2023
·
Timothy J Straub
, Mary-Jane Lombardo
, et al.
·
Clinical Infectious Diseases
·
18
PDF
Microbiota-Based Therapeutics as New Standard-of-Care Treatment for Recurrent Clostridioides difficile Infection
2024
·
Johannes Stallhofer
, Arndt Steube
, et al.
·
Visceral Medicine
·
15
PDF
The perils of PCR-based diagnosis of Clostridioides difficile infections: Painful lessons from clinical trials
2019
·
Ling Yuan Kong
, Kerrie Davies
, et al.
·
Anaerobe
·
14
PDF
The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome
2026
·
Jessica A. Bryant
, Marin Vulić
, et al.
·
Nature Medicine
·
13
Show more works
View as search
Works count:
112
Citation count:
2,422
Year
Topic
Type